Clinical trial · Interventional
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
txt4TKI: An Innovative Mobile Intervention to Improve Tyrosine Kinase Inhibitor Management Among Chronic Myeloid Leukemia Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid leukemia. Tyrosine kinase inhibitors (TKI) are associated with numerous potential side effects, including a decrease in bone marrow activity (myelosuppression), nausea, diarrhea, fatigue, and soft-tissue swelling (edema), especially in the face and lower legs, which are the primary reasons for patients to discontinue TKI medication. Using a mobile text messaging (TXT) intervention that emphasizes the importance of TKI compliance may improve TKI adherence in patients with chronic myeloid leukemia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
| Chronic Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Survey Administration | Other | — | UNRESOLVED |
| Text Message-Based Navigation Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Text message intervention
- description
- Six month text message intervention
- interventionNames
- Other: Text Message-Based Navigation Intervention
- Other: Survey Administration
Primary outcomes (18)
- measure
- Assessment of TKI Treatment Date
- timeFrame
- Up to 6 months post-baseline
- description
- Will be extracted from the electronic medical record (EMR) chart, including tyrosine kinase inhibitor (TKI) treatment initiation dates
- measure
- Assessment of TKI Treatment change
- timeFrame
- Up to 6 months post-baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * PHASE 1: Patients diagnosed with chronic myeloid leukemia * PHASE 1: Initiated tyrosine kinase inhibitors therapy for a year * PHASE 1: Able to read and understand English * PHASE 1: Able to provide informed consent * PHASE 1: Have a mobile phone with TXT capability * PHASE 1: Know how to use TXT * PHASE 2: Patients diagnosed with chronic myeloid leukemia in the chronic phase * PHASE 2: Starting tyrosine kinase inhibitors therapy or has been on tyrosine kinase inhibitors with anticipation of at least 6 month duration of use * PHASE 2: Able to read and understand English * PHASE 2: Able to provide informed consent * PHASE 2: Have a mobile device with TXT capability * PHASE 2: Willing to use a wireless pill bottle during study for 6 months * PHASE 2: Know or willing to learn how to use TXT Exclusion Criteria: • Cognitive impaired document in the electronic medical record (EMR)
References
Publications (0)
Data not yet available